

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

GRANT OF SHARE OPTIONS

This announcement is made by Peijia Medical Limited (the “**Company**”) pursuant to Rule 17.06A of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby announces that on June 26, 2026, the Company granted share options (the “**Share Option(s)**”) to certain eligible participants (the “**Grantee(s)**”) to subscribe for a total of 2,332,800 ordinary shares of the Company (the “**Share(s)**”), subject to and upon the terms and conditions of the share option scheme adopted by the Company on April 28, 2020 (the “**Share Option Scheme**”). Details of the Share Options granted are set out as follows:

Date of grant:	June 26, 2026 (the “ Date of Grant ”)
Description of the Grantees:	Employees of the Company, none of whom is (i) a Director, chief executive or substantial shareholder of the Company or any of their respective associates (as defined in the Listing Rules); (ii) a participant with options and awards granted and to be granted exceeding the 1% individual limit under Rule 17.03D of the Listing Rules; or (iii) a related entity participant or service provider with options and awards granted and to be granted in any 12-month period exceeding 0.1% of the total issued Shares (excluding treasury shares), as of the date of this announcement.

Number of Share Options granted:	2,332,800 Share Options (each Share Option shall entitle the Grantees to subscribe for one Share)
Exercise price of the Share Options granted:	HK\$4.028 per Share, representing the highest of: (i) HK\$3.77, being the closing price of the Shares as stated in the daily quotations sheet by the Stock Exchange on the Date of Grant; and (ii) HK\$4.028, being the average of the closing prices of the Shares as stated in the daily quotations sheet by the Stock Exchange for the five business days immediately preceding the Date of Grant, subject to adjustments under the terms of the Share Option Scheme in accordance with Rule 17.03(13) of the Listing Rules.
Validity and exercise period of the Share Options:	The Share Options are valid and exercisable for a period of 10 years from the Date of Grant.
Vesting period of the Share Options:	Subject to the rules of the Share Option Scheme, 30% of the Share Options granted will vest on the first anniversary of the Date of Grant; 30% of the Share Options granted will vest on the second anniversary of the Date of Grant; 40% of the Share Options granted will vest on the third anniversary of the Date of Grant.
Performance targets attached to the Share Options:	The Grantees must (i) achieve Grade B or above in their respective performance appraisals; and (ii) remain as employees of the Company when the relevant Share Options are vested.
Financial assistance:	The Group has not provided any financial assistance to the Grantees to facilitate the purchase of Shares under the Share Option Scheme.

Subsequent to the grant of the Share Options, the number of Shares available for future grant pursuant to the Share Option Scheme is 54,294,584 Shares.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, June 26, 2026

As at the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Mr. Jifeng GUAN, Mr. Fei CHEN and Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP and Mr. Huacheng WEI as independent non-executive Directors.